临床试验登记· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · ClinicalTrials.gov·· 3 小时前评分29
Chidamide联合Benmelstobart、Nab-paclitaxel和SBRT作为晚期BTC二线治疗
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
导读
2期单臂多中心临床试验将评估Chidamide联合Benmelstobart、Nab-paclitaxel和SBRT作为晚期BTC二线治疗。NCT07890506计划纳入41例既往接受一线系统治疗的BTC患者，尚未招募，计划于2026-11-01启动；主要终点为PFS，次要终点为ORR、DoR、OS及安全性。
来源：临床试验登记 · clinicaltrials.gov